{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2005"],"condition":["Colorectal Carcinoma","Colorectal Neoplasms"],"disease":["Colorectal Carcinoma","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2020680"],"location":["Portugal"],"study_start_month":["7"],"keyword":["Cetuximab"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer","description":"The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.\nThis study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.","dates":{"creation":"2005-07-15"},"accession":"2020680","cross_references":{"ClinicalTrials___gov":["NCT00215722"]}}